Foundation Medicine Inc. and Clovis Oncology Inc. said today they will work together to develop an in-vitro test for identifying biomarkers in specific cancer patients who would most likely respond to a Clovis drug. <\/p>\n
The companies said they will analyze the genomic alterations found in tissue samples from patients to evaluate the feasibility of developing an in-vitro diagnostic method to identify patients, including those with ovarian cancer, with tumors most likely to respond to the drug rucaparib. <\/p>\n
Foundation Medicine is a Cambridge-based molecular information company. Clovis, a biopharmaceutical company, is based in Boulder, Colo. <\/p>\n
Foundation Medicines core capability is the translation of genomic insights into clinically actionable information, said company president and CEO Michael Pellini. But even the most in-depth genomic profile for a patient is only as actionable as the available and relevant targeted therapies. Therefore, we are working to help expand the universe of targeted therapeutic options. Clovis Oncology, a recognized leader in patient specific oncology drug development, is an ideal partner in this mission. <\/p>\n<\/p>\n
Read the original here: <\/p>\n
Cambridge's Foundation Medicine launches drug collaboration<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Foundation Medicine Inc. Continue reading